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levels, although always within the normal range, were 
found higher in Group B than Group A after 12 months 
(p = 0.015).
Conclusions According to the new AIFA criteria, the 
reduction of GH cut-off for GHD diagnosis can be sup-
ported by auxological and metabolic data. The real benefits 
from GH therapy in children with higher stimulated GH 
levels at diagnosis remains to be better understand.
Keywords Growth hormone deficiency · Children · 
Italian Medicines Agency (AIFA)
Introduction
The diagnosis of growth hormone (GH) deficiency (GHD) 
in childhood has been and remains object of much contro-
versy [1–3]. The condition of GHD is established by the 
clinical, auxological and biochemical criteria of the GH 
Research Society [4]. As regards the biochemical assess-
ment, limited and discordant data for each stimulation test 
exist. However, in children with appropriate clinical crite-
ria for GHD, a peak concentration below 10 μg/L has tra-
ditionally been used to support the diagnosis, although an 
overlap could exist in GH peak between normal and GHD 
children [4]. For these reasons, in the absence of a gold 
standard test or cut-off, it is important to integrate clini-
cal, auxological, radiological and biochemical criteria to 
diagnose GHD. In Italy, we recently had a review of the 
criteria of appropriateness of use and reimbursement of 
GH treatment in children according to the note 39 of the 
Italian Medicines Agency (AIFA). The critical analysis 
of the newly proposed note mainly focused on the cut-off 
of GH. As explicitly indicated in the new note, as regards 
the biochemical criteria, children need to show a GH peak 
Abstract 
Purpose This study aimed at evaluating the clinical and 
metabolic behavior of children with isolated growth hor-
mone (GH)-deficiency (GHD), grouped according to the 
new AIFA criteria for the appropriateness of use and reim-
bursement of GH treatment in children.
Methods The clinical and metabolic data of 310 prepuber-
tal children (220 M, 90 F; mean age 10.8 years) grouped, 
according to new AIFA note 39, into Group A (No. 181 
with a peak of GH <8 µg/l), Group B (No. 103 with a peak 
of GH ≥8 and <10 µg/l) and Group C (No. 26 with a peak 
of GH >10 µg/l) were retrospectively analyzed. Group A 
and B, diagnosed as having GHD, were treated with GH 
for at least 24 months, while Group C was analyzed only at 
baseline.
Results At baseline, Group A showed higher waist cir-
cumference than B (p = 0.031) and C (p = 0.041), while no 
difference in metabolic parameters was found between the 
three groups. After 12 and 24 months of treatment, Group 
B showed lower height velocity (p < 0.001 and p = 0.049, 
respectively) than Group A. As regards the metabolic 
parameters, both after 12 and 24 months of treatment, in 
Group B we found higher fasting glucose (p < 0.001 and 
p = 0.020), insulin (p = 0.002 and p = 0.011), Homa-β 
(p = 0.020 and p = 0.015) and Homa-IR (both p = 0.001) 
than Group A, with concomitant lower QUICKI (both 
p < 0.001) and HDL cholesterol (p = 0.020 and p = 0.011), 
without difference in other lipid parameters. The HbA1c 
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<8 μg/L after two different GH provocation tests to be 
diagnosed as having GHD. It is noteworthy that, by apply-
ing these new criteria, a percentage of children previously 
diagnosed as having GHD may have received a wrong 
diagnosis and an unnecessary treatment, with potential 
clinical implications and increased healthcare spending. 
On the other hand, whether the under-treatment of these 
patients could have consequences with regard to health is 
not known. The aim of this study was to evaluate the clini-
cal and metabolic behavior of GH-treated children grouped 
according to the new AIFA criteria.
Materials and methods
We retrospectively analyzed the clinical and metabolic 
data of 310 consecutive prepubertal children (220 males, 
90 females, mean age 10.8 ± 2.9 years; range 3.7–14.0 
years) with short stature consecutively admitted to the Sec-
tion of Endocrinology of the University of Palermo during 
the years 2005–2013. All children underwent arginine test 
[0.5 g/kg body weight (no more than 30 g) of arginine over 
30 min] and glucagon test [im administration of 30 μg/kg 
glucagon (no more than 1 mg)] on two different days and 
were divided, according to new AIFA note 39, into Group 
A (No. 181 with a peak of GH <8 µg/l after two tests), 
Group B (No. 103 with a peak of GH ≥8 and <10 µg/l) and 
Group C (No. 26 with a peak of GH >10 µg/l). Groups A 
and B, diagnosed as having GHD, were treated with GH 
for at least 24 months, while Group C, without GHD, was 
analyzed only at baseline and it was considered as a con-
trol healthy group. Among children of Group C, 15 (58 %) 
were diagnosed as having idiopathic short stature (ISS) and 
11 (42 %) as having constitutional delay of growth. Neu-
roimaging, with magnetic resonance imaging (MRI) of the 
hypothalamic-pituitary region, was arbitrarily performed in 
accordance with our internal protocol only in GHD children 
with more severe GHD, i.e. with GH peak ≤3 µg/l (No. 43 
children). Among them, six patients showed a partial empty 
sella and 2 a pituitary hypoplasia. We excluded children 
affected by multiple pituitary hormone deficiency or receiv-
ing any other kind of hormonal replacement therapy or drug 
and GHD children with a shorter follow-up. All children, 
even the older ones, were in the first or second stage (due 
to the presence of initial pubic hairs) of sexual development 
according to the Marshall and Tanner criteria [5] to avoid 
any interference of puberty on auxological and metabolic 
parameters and maintained the prepubertal hormonal status 
during the observation period (i.e. FSH and LH <1 mU/ml, 
total testosterone and 17β-Estradiol <0.50 ng/ml and <5 pg/
ml, respectively, in males and females). In particular, in 
Groups A and B, the pubertal status was, respectively, stage 
I in 160/181 and 91/103 and stage II in 21/181 and 12/103 
subjects at baseline, and stage I in 142/181 and 78/103, 
stage II in 39/181 and 25/103 subjects after 24 months of 
follow-up, while in the control group 21/26 children were 
in the stage I and 5/26 in the stage II.
The diagnosis of GHD was established by the GH 
Research Society criteria [4]. GHD was demonstrated by 
failure of GH to respond to the two stimuli (arginine and 
glucagon tests) with GH peaks below 10 µg/l. The GHD 
patients received GH once daily at bedtime with a pen 
injection system. During the follow-up, in line with our 
internal fixed protocol, in all children, regardless of GH 
peak, we used an initial daily dose of 0.025 mg/kg of GH 
with a gradual increase of 0.003–0.005 mg/kg/day every 
6 months to always maintain the IGF-I levels in the normal 
range. In detail, from months 1 to 6 all children were main-
tained at a mean dose of 0.025 mg/kg/day, from months 6 
to 12 at a mean dose of 0.029 mg/kg/day and from months 
12 to 24 at the dose of 0.033–0.035 mg/kg/day.
Study protocol
In all GHD patients, at baseline and after 12 and 24 months 
of GH treatment, according to our fixed internal protocol, we 
measured body height (Standard Deviation, SD), body mass 
index (BMI) and waist circumference (WC). Blood sam-
ples were drawn after an overnight fast. Laboratory assess-
ment included fasting glucose and insulin levels, insulin-like 
growth factor-I (IGF-I), glycosylated hemoglobin (HbA1c), 
lipid profile including total cholesterol, high-density cho-
lesterol (HDL) and triglycerides. Low-density lipoprotein 
(LDL) cholesterol levels were evaluated by the formula: 
Estimates of basal insulin secretion included fasting insu-
lin and the homeostasis model assessment for β-cell func-
tion index (Homa-β) [6]. As surrogate estimates of insulin 
sensitivity we considered the homeostasis model assess-
ment estimate of insulin resistance (Homa-IR) [6] and the 
quantitative insulin sensitivity check index (QUICKI) [7]. 
In the control subjects, this evaluation was performed only 
at baseline.
The institutional Ethics Committee of the University of 
Palermo approved this study. At the time of hospitaliza-
tion informed consent for the scientific use of the data was 
obtained from all parents of the participants.
Hormone and biochemical assays
All biochemical data were collected after overnight fast-
ing. Glycemia and HbA1c were measured in the central-
ized accredited laboratories with standard methods. Serum 
insulin was measured by ELISA (DRG Instruments GmbH, 
LDL cholesterol = total cholesterol− HDL cholesterol
− triglycerides/5.
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Germany). The sensitivity of the method was 1 IU/ml. The 
normal insulin range (IU/ml) was 5–19. Throughout the 
follow-up, GH levels were assayed by immunoradiomet-
ric assay (Radim, Pomezia, Italy) and the sensitivity of the 
assay was 0.05 µg/l. The intra and inter-assay coefficients 
of variation (CV) were 2.5–3.9 and 3.8–5.0 %, respec-
tively. Serum total IGF-I was assayed in the same labora-
tory with the ELISA method (OCTEIA IGF-I kit, IDS Inc., 
Fountain Hills, AZ, USA). The sensitivity of the method 
was 1.9 µg/l. The inter- and intra-assay CV values were 
7–7.1 and 2.3–3.5 %, respectively, at IGF-I levels of 90.7–
186 and 66.7–120.9 µg/l, respectively. The normal ranges 
(males and females combined) of total IGF-I levels (µg/l) 
were 12–108 (0–1 years); 13–100 (1–3 years); 26–280 
(3–6 years); 85–230 (6–9 years); 98–404 (9–12 years); 
142–525 (12–15 years); 146–415 (15–20 years).
Statistical analysis
The Statistical Packages for Social Sciences (SPSS) ver-
sion 17 was used for data analysis. Baseline characteristics 
were presented as mean ± standard deviation (SD); rates 
and proportions were calculated for categorical data. The 
normality of distribution of the quantitative variables was 
assessed with the Kolmogorov–Smirnov test. Only the M 
value did not show a normal distribution. The differences 
between the three groups of children at baseline were eval-
uated by ANOVA univariate post hoc test analysis. The dif-
ferences between the two groups of GHD children (Group 
A and Group B) were evaluated by the Student’s t test for 
the data with a normal distribution and by Mann–Whitney 
U-test (non-parametric test) for continuous variables with-
out normal distribution (M value). Differences in meta-
bolic parameters were corrected for BMI through a logistic 
regression model. A p value of <0.05 was considered statis-
tically significant.
Results
The clinical and biochemical features of all children, 
grouped according to cut-off of GH, are shown in Tables 1 
and 2.
No difference was found for age between the three 
groups of children (Table 1). At baseline, Group A 
showed higher waist circumference (63.3 ± 11.1 cm) 
than B (58.6 ± 11 cm; p = 0.031) and C (58.6 ± 8.2 cm; 
p = 0.041), while no difference in metabolic param-
eters was found between the three groups. As expected, 
Group C showed a better height (−1.70 ± 0.35 SD) than 
A (−2.04 ± 0.72 SD; p = 0.002) and B (−2.06 ± 0.86 
SD; p = 0.010), with concomitant higher IGF-1 levels 
(p = 0.013 and 0.015, respectively) (Table 1).
After 12 and 24 months of treatment, Group B showed 
lower height velocity (7.4 ± 2.2 vs. 8.6 ± 2.5 cm; p < 0.001 
and 5.8 ± 1.2 vs. 7.7 ± 8.7 cm; p = 0.049, respectively) 
than Group A, with a concomitant lower, although not sta-
tistically significant, height SD and without difference in 
BMI, WC and IGF-1 levels (Table 2).
As regards the metabolic parameters, after 12 months of 
treatment both in Groups A and B we found a significant 
increase in fasting glucose (both p < 0.001), fasting insulin 
(both p < 0.001), Homa-IR (both p < 0.001), Homa-β (both 
p < 0.001) and HbA1c (both p < 0.001), with a concomitant 
decrease in QUICKI (both p < 0.001), without further sig-
nificant change after 24 months. No significant difference 
was found in total and HDL-cholesterol and triglycerides in 
both groups from baseline to 24 months, while a significant 
decrease in LDL-cholesterol was found from baseline to 
12 months only in Group A (p = 0.010) (data not shown).
When we analyzed the difference between the two 
groups of GHD children, both after 12 and 24 months of 
treatment in Group B we found higher fasting glucose 
(5.18 ± 0.40 vs. 4.86 ± 0.55 mmol/L; p < 0.001 and 
5.07 ± 0.35 vs. 4.89 ± 0.50 mmol/L; p = 0.015), fast-
ing insulin (12.9 ± 5 vs. 9 ± 6.2 IU/ml; p = 0.002 and 
12.7 ± 4.4 vs. 9.6 ± 5.3 IU/ml; p = 0.011), Homa-β 
(46.2 ± 1.9 vs. 33.4 ± 2.4 %; p = 0.020 and 47.8 ± 1.6 vs. 
36.4 ± 2.2 %; p = 0.015) and Homa-IR (3.02 ± 1.22 vs. 
2.02 ± 1.48; p = 0.001 and 3.01 ± 0.96 vs. 2.08 ± 1.15; 
p = 0.001) than Group A, with concomitant lower QUICKI 
(0.32 ± 0.01 vs. 0.36 ± 0.04; p < 0.001 and 0.32 ± 0.01 vs. 
0.35 ± 0.03; p < 0.001) and HDL cholesterol (54.5 ± 11.4 
vs. 58.8 ± 13 mgdl; p = 0.020 and 53.1 ± 11.7 vs. 
59.4 ± 12.2 mg/dl; p = 0.011), without difference in other 
lipid parameters. The HbA1c levels, although always 
within the normal range, was found higher in Group B 
than Group A after 12 months of treatment (5.3 ± 0.3 vs. 
5.1 ± 0.3 %, p = 0.015), but not after 24 months (Fig. 1; 
Table 2)
When we performed the same analysis by grouping all 
children according to gender, we did not found significant 
difference between males and females (data not shown).
Discussion
Although recombinant human GH has been available since 
1985, there are several unanswered questions related to its 
use. To date a clear benefit-risk profile in some specific 
groups of treated children, i.e. in the milder forms of GHD 
or in ISS, is still not well defined. Children with ISS are 
distinguished from GHD children by an arbitrary cut-off 
in peak stimulated GH secretion and the ISS indication is 
approved in the USA and not in Europe [8]. Despite the 
GH Research Society has well established the clinical, 
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auxological and biochemical criteria for the diagnosis of 
GHD [4], many questions remain about the proper diag-
nosis in children [9]. Many different stimuli are currently 
used to induce GH secretion, but to date no stimulation 
test is completely reliable. The provocative tests are poorly 
reproducible, the GH cut-off is quite arbitrary and the GH 
peak response could be influenced by many factors, such 
as age, BMI, adiposity or pubertal status [10–13]. Some 
years ago Kristrom et al. demonstrated that the growth 
response in ISS was similar to GHD children, despite the 
first required higher dose of GH [14], while other authors 
have demonstrated that there is no benefit in treating these 
groups of children [15, 16]. In addition, similar proportions 
of poor responders to treatment have been found in ISS and 
GHD children, which probably indicates that there is not 
a different underlying pathology in most of these patients, 
except for those with severe GHD with a GH peak <3 µg/l 
[17]. Despite that pharmacological tests are not completely 
reliable and are burdened by poor specificity because they 
test the GH-IGF-I axis in a non-physiological manner 
[18–20], measuring GH secretion after provocative tests is 
necessary to regulate the use of GH and is still considered 
the gold standard in the diagnosis of GHD, according to the 
well-established criteria. To date the cut-off <10 µg/l after 
two tests has commonly used [4]. However, there is little 
evidence to support this classically suggested cut-off, set 
rather arbitrarily and without adjusting for the above men-
tioned factors. This may lead to misdiagnosis GHD. Indeed, 
up to 85 % of short children who were diagnosed as having 
GHD with peak GH <10 µg/l in two provocative tests had a 
normal GH response when retested a few months later [21]. 
Despite this, the cut-off level for the diagnosis of GHD has 
not yet been revised [22].
In Italy, the criteria of appropriateness of use of GH 
treatment in children have been recently revised and the 
cut-off of GH after a stimulation test to make a diagnosis of 
Table 1  Baseline clinical and biochemical features of all children grouped according to cut-off of GH after stimulation test (Group A: peak of 
GH <8 µg/l; Group B peak of GH ≥8 and <10 µg/l; Group C peak of GH >10 µg/l)
* p difference between Group A and B
** p difference between Group A and C
*** p difference between Group B and C
a
 Mean GH peak after glucagon and arginine test
GHD
Group A (No. 181)
GHD
Group B (No. 103)
Controls Group C (No. 26) p* p** p***
Subjects (%) Subjects (%) Subjects (%)
Gender
 Males 136 (75) 72 (70) 12 (46) 0.413 0.004 0.041
 Females 45 (25) 31 (30) 14 (54)
Mean ± SD Mean ± SD Mean ± SD p* p** p***
Age (years) 10.7 ± 2.9 10.8 ± 2.8 11.3 ± 2.9 0.746 0.331 0.432
Height (SD) −2.04 ± 0.72 −2.06 ± 0.86 −1.70 ± 0.35 0.935 0.040 0.010
Height velocity (cm/year) 3.7 ± 1.5 4.2 ± 1.2 4.1 ± 1.7 0.098 0.122 0.745
BMI (kg/m2) 17.7 ± 3.3 17.3 ± 3.2 16.6 ± 3.1 0.352 0.102 0.295
WC (cm) 63.3 ± 11.1 58.6 ± 11 58.6 ± 8.2 0.031 0.041 0.991
IGF-1 (µg/l) 119 ± 68.7 121 ± 64 199 ± 108 0.829 <0.001 0.015
GH peaka (µg/l) 3.4 ± 1.6 8.5 ± 1.8 14.2 ± 5.4 <0.001 <0.001 <0.001
Fasting glucose (mmol/L) 4.45 ± 0.57 4.57 ± 0.68 4.28 ± 0.60 0.159 0.152 0.057
Fasting insulin (IU/ml) 4.9 ± 4 5.7 ± 8.1 3.8 ± 2.8 0.586 0.231 0.292
HbA1c (%) 4.9 ± 0.4 4.9 ± 0.5 5.2 ± 0.3 0.477 0.060 0.140
Homa-β (%) 18.7 ± 1.7 24.9 ± 5 15 ± 1.3 0.468 0.343 0.348
Homa-IR 1 ± 0.88 1 ± 1.42 0.72 ± 0.54 0.697 0.152 0.238
QUICKI 0.42 ± 0.10 0.44 ± 0.13 0.46 ± 0.13 0.452 0.189 0.581
Total cholesterol (mg/dl) 163.3 ± 30.5 156.6 ± 29.2 164.5 ± 30.2 0.118 0.857 0.259
HDL cholesterol (mg/dl) 58.2 ± 13.4 56.2 ± 13.2 63.2 ± 14.5 0.284 0.104 0.055
LDL cholesterol (mg/dl) 92.2 ± 27.5 87.8 ± 29.2 87.6 ± 24.8 0.352 0.839 0.384
Triglycerides (mg/dl) 66.7 ± 34 62.6 ± 24.5 68.3 ± 35.2 0.277 0.453 0.972
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GHD has been arbitrarily reduced from 10 to 8 μg/l. Retro-
spectively applying this new cut-off to a series of patients 
already diagnosed as GHD and treated with GH, we found 
that 36 % of children showed a GH peak between 8 and 
10 μg/l. In this group of subjects, considered as affected 
by GHD on the basis of previous, but not current, AIFA 
criteria, we found a worse auxological response during 
24 months of GH treatment. Indeed, these children showed 
a lower height velocity than children with a GH peak 
<8 μg/l. In addition, when the metabolic parameters were 
analyzed, at baseline children with lower GH peak showed 
higher WC than children with GH peak between 8 and 
10 μg/l and this finding could be a sign of a real condition 
of GHD [23].
During the follow-up, the evidence that children of 
Group B showed a worse metabolic profile probably con-
firms that the previous cut-off of 10 seems to be too high. 
We found higher glucose and insulin levels with higher 
insulin resistance degree in this group of children, concomi-
tant with higher insulin-secretion. This trend to impairment 
in glucose metabolism during GH treatment has often been 
previously demonstrated [24, 25]. It is well known that GH 
treatment leads to a decrease in insulin sensitivity and alter-
ation in insulin secretion even without evident changes in 
glucose tolerance [26] and the current study confirms this 
finding. Indeed, particularly after the first 12 months of GH 
treatment, we found a worsening trend of insulin sensitiv-
ity, as documented by increase in fasting glucose and insulin 
levels, Homa-IR and HbA1c, in both groups of GHD chil-
dren and this trend was greater in Group B. This finding 
is consistent with the data of Salerno et al. which showed 
in children during GH treatment that the HOMA index 
increased more significantly in the group with partial than 
those with severe GHD [27]. In addition, the children of the 
Group A showed a decrease in LDL cholesterol during the 
first 12 months of treatment and higher HDL cholesterol 
than Group B throughout the follow-up. These evidences 
could demonstrate that children with higher baseline stimu-
lated GH levels may not fully benefit from the GH treatment 
as well as the children with more severe GHD. Therefore, a 
percentage of children previously diagnosed with GHD may 
have been misdiagnosed and may have received an unnec-
essary treatment, with potential clinical implications. These 
data could be confirmed during the future follow-up when 
children, after reaching the adult height, will be subject to 
retesting of GH axis. Indeed, to date, 60–85 % of patients 
diagnosed with GHD in childhood will have adequate GH 
secretion when retested in late adolescence or adulthood 
[28–30] and these data could reflect a wrong diagnosis of 
GHD. When the diagnosis of GHD in children is made with 
the new more selective GH cutoff proposed by AIFA, proba-
bly the percentage of GHD children not confirmed by retest-
ing in the transition period may be reduced.
A limit of this study is likely represented by the use of 
similar doses of GH in the two groups of children. Indeed, 
discordant data exist about the different metabolic effects of 
Table 2  Clinical and biochemical features of children grouped according to cut-off of GH after stimulation test (Group A: peak of GH <8 µg/l; 
Group B peak of GH ≥8 and <10 µg/l) after 12 and 24 months of GH treatment
* p value corrected for BMI
GHD
Group A (No. 181)
GHD
Group B (No. 103)
p p* GHD
Group A (No. 181)
GHD
Group B (No. 103)
p p*
12 months 24 months
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Height (SD) −1.58 ± −0.66 −1.55 ± 0.79 0.853 −1.33 ± 0.77 −1.17 ± 0.91 376
Height velocity (cm/year) 8.6 ± 2.5 7.4 ± 2.2 0.001 7.7 ± 8.7 5.8 ± 1.2 0.049
BMI (kg/m2) 18 ± 3.3 17.9 ± 3.4 0.710 18.3 ± 3.3 18.1 ± 3 0.667
WC (cm) 64.4 ± 10.2 65.5 ± 11.1 0.616 66.8 ± 11.6 69 ± 7.4 0.349
IGF-1 (µg/l) 311 ± 181 321 ± 161 0.695 331 ± 191 352 ± 142 0.509
Fasting glucose (mmol/l) 4.86 ± 0.55 5.18 ± 0.40 <0.001 <0.001 4.89 ± 0.50 5.07 ± 0.35 0.015 0.020
Fasting insulin (IU/ml) 9 ± 6.2 12.9 ± 5 0.001 0.002 9.6 ± 5.3 12.7 ± 4.4 0.011 0.011
HbA1c (%) 5.1 ± 0.3 5.3 ± 0.3 0.016 0.015 5.1 ± 0.3 5.2 ± 0.3 0.190 0.200
Homa-β (%) 33.4 ± 2.4 46.2 ± 1.9 0.007 0.020 36.4 ± 2.2 47.8 ± 1.6 0.014 0.015
Homa-IR 2.02 ± 1.48 3.02 ± 1.22 0.001 0.001 2.08 ± 1.15 3.01 ± 0.96 0.001 0.001
QUICKI 0.36 ± 0.04 0.32 ± 0.01 <0.001 <0.001 0.35 ± 0.03 0.32 ± 0.01 <0.001 <0.001
Total cholesterol (mg/dl) 163 ± 29 156.9 ± 28.1 0.175 160.7 ± 24.4 149.4 ± 36.7 0.093
HDL cholesterol (mg/dl) 58.8 ± 13 54.5 ± 11.4 0.030 0.020 59.4 ± 12.2 53.1 ± 11.7 0.011 0.011
LDL cholesterol (mg/dl) 89.1 ± 26.8 89 ± 29.2 0.998 88.7 ± 24.5 81.7 ± 36.5 0.242
Triglycerides (mg/dl) 74.2 ± 31.4 66.1 ± 27.7 0.076 62.2 ± 22.1 75.4 ± 36.7 0.054
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different dose used [31] and a larger prospective study where 
patients of both groups are randomized to different GH doses 
can give more complete information. Furthermore, the short-
term clinical and metabolic evaluation performed in this 
study does not allow to affirm with certainty that children 
with a GH peak between 8 and 10 µg/l cannot fully benefit 
from GH therapy and a longer follow-up would be required.
In conclusion, this study demonstrates that the reduc-
tion of the GH cut-off can probably be supported by aux-
ological and metabolic data, since children with lower 
levels of stimulated GH show a better response to treat-
ment, although a degree of growth improvement in Group 
B is also to be considered. The real clinical and metabolic 
benefits from GH therapy in this group of children with 
higher stimulated GH levels at diagnosis, as well as in other 
non-GHD groups of patients currently treated (i.e. chil-
dren with Turner syndrome, born small for gestational age, 
ISS), remains to be better understood. We need more well-
designed long-term studies with large number of patients 
looking at different subgroups of children, also according 
to GH cut-off, to better assess their different auxological 
and metabolic response to treatment.
Conflict of interest The authors declare that they have no conflict 
of interest.
Ethical approval All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards
Informed consent Informed consent for the scientific use of the 
data was obtained from all individual participants included in the 
study and from their parents.
Funding This research did not receive any specific grant from any 
funding agency in the public, commercial or not-for-profit sector.
References
 1. Drug and Therapeutics Committee of the Lawson Wilkins Pedi-
atric Endocrine Society. (1995) Guidelines for the use of growth 
hormone in children with short stature. A report by the Drug and 
Therapeutics Committee of the Lawson Wilkins Pediatric Endo-
crine Society. J Pediatr 127(6):857–867
 2. American Academy of Pediatrics (1997) Considerations related 
to the use of recombinant human growth hormone in children. 
American Academy of Pediatrics Committee on Drugs and Com-
mittee on Bioethics. Pediatrics 99(1):122–129
 3. Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, 
Chaussain JL, Savage MO (1998) Diagnosis and treatment of 
growth hormone deficiency in children and adolescents: towards 
a consensus. Ten years after the Availability of Recombinant 
Human Growth Hormone Workshop held in Pisa, Italy, 27–28 
March 1998. Horm Res 50(6):320–340
 4. Growth Hormone Research Society (2000) Consensus guidelines 
for the diagnosis and treatment of growth hormone (GH) defi-
ciency in childhood and adolescence: summary statement of the 
GH Research Society. J Clin Endocrinol Metab 85:3990–3993
 5. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal 
changes in girls. Arch Dis Child 44(235):291
 6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher 
DF, Turner RC (1985) Homeostasis model assessment: insulin 
resistance and beta-cell function from fasting plasma glucose 
and insulin concentrations in man. Diabetologia 28(7):412–419
 7. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sul-
livan G, Quon MJ (2000) Quantitative insulin sensitivity check 
index: a simple, accurate method for assessing insulin sensitivity 
in humans. J Clin Endocrinol Metab 85(7):2402–2410
Fig. 1  Fasting glucose (mmol/L), HbA1c (%) and Homa-IR in chil-
dren grouped according to GH peak after stimulation test into Group 
A (No. 181 with a peak of GH <8 µg/l), Group B (No. 103 with a 
peak of GH ≥8 and <10 µg/l) and Group C (No. 26 with a peak of 
GH >10 µg/l) at baseline and after 12 and 24 months of GH treatment 
(in Group A and B)
Author's personal copy
J Endocrinol Invest 
1 3
 8. Wit JM, Bang P (2008) European perspective on treatment 
approaches for growth failure. Pediatr Endocrinol Rev 5(Suppl 
3):862–868
 9. Rigamonti AE, Bozzola M, Banfi G, Meazza C, Müller EE, Cella 
SG (2012) Growth hormone variants: a potential avenue for a 
better diagnostic characterization of growth hormone deficiency 
in children. J Endocrinol Invest 35(10):937–944
 10. Lee HS, Hwang JS (2011) Influence of body mass index on 
growth hormone responses to classic provocative tests in chil-
dren with short stature. Neuroendocrinology 93(4):259–264
 11. Di Somma C, Ciresi A, Amato MC, Savastano S, Savanelli 
MC, Scarano E, Colao A, Giordano C (2014) Alteration of the 
growth hormone axis, visceral fat dysfunction, and early cardio-
metabolic risk in adults: the role of the visceral adiposity index. 
Endocrine Nov 9 (Epub ahead of print)
 12. Stanley T (2012) Diagnosis of growth hormone deficiency in 
childhood. Curr Opin Endocrinol Diabetes Obes 19(1):47–52
 13. Loche S, Guzzetti C, Pilia S, Ibba A, Civolani P, Porcu M, Min-
erba L, Casini MR (2011) Effect of body mass index on the 
growth hormone response to clonidine stimulation testing in 
children with short stature. Clin Endocrinol (Oxf) 74(6):726–731
 14. Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin 
M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Alberts-
son-Wikland K (2009) Growth hormone (GH) dosing during 
catch-up growth guided by individual responsiveness decreases 
growth response variability in prepubertal children with GH 
deficiency or idiopathic short stature. J Clin Endocrinol Metab 
94(2):483–490
 15. Elder CJ, Barton JS, Brook CG, Preece MA, Dattani MT, Hind-
marsh PC (2008) A randomised study of the effect of two doses 
of biosynthetic human growth hormone on final height of chil-
dren with familial short stature. Horm Res 70(2):89–92
 16. Zucchini S, Wasniewska M, Cisternino M, Salerno M, Iughetti 
L, Maghnie M, Street ME, Caruso-Nicoletti M, Cianfarani S 
(2008) Adult height in children with short stature and idiopathic 
delayed puberty after different management. Eur J Pediatr 
167(6):677–681
 17. Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul 
A, Kriström B, Tapanainen P, Aberg V (2011) A comparison 
of different definitions of growth response in short prepuber-
tal children treated with growth hormone. Horm Res Paediatr 
75(5):335–345
 18. Dattani MT, Pringle PJ, Hindmarsh PC, Brook CG (1992) What 
is a normal stimulated growth hormone concentration? J Endo-
crinol 133(3):447–450
 19. Hindmarsh PC, Swift PG (1995) An assessment of growth hor-
mone provocation tests. Arch Dis Child 72(4):362–367
 20. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT (2014) Iso-
lated growth hormone deficiency (GHD) in childhood and ado-
lescence: recent advances. Endocr Rev 35(3):376–432
 21. Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C, Autelli 
M, Casini MR, Cappa M (2002) Results of early reevaluation of 
growth hormone secretion in short children with apparent growth 
hormone deficiency. J Pediatr 140(4):445–449
 22. Tenenbaum-Rakover Y (2008) The need to revise the cut-off 
level for the diagnosis of GH deficiency in children. Pediatr 
Endocrinol Rev 5(4):880–888
 23. Capalbo D, Esposito A, Di Mase R, Barbieri F, Parenti G, 
Vajro P, Pignata C, Salerno M (2012) Update on early cardio-
vascular and metabolic risk factors in children and adolescents 
affected with growth hormone deficiency. Minerva Endocrinol 
37(4):379–389
 24. Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, 
Meli R, Bruzzese D, Salerno M (2013) Cluster of cardiometa-
bolic risk factors in children with GH deficiency: a prospective, 
case-control study. Clin Endocrinol (Oxf) 80(6):856–862
 25. Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Gal-
luzzo A, D’Acquisto G, Giordano C (2007) Metabolic param-
eters and adipokine profile during GH replacement therapy in 
children with GH deficiency. Eur J Endocrinol 156(3):353–360
 26. Ciresi A, Amato MC, Giordano C (2014) Reduction in insu-
lin sensitivity and inadequate β-cell capacity to counteract the 
increase in insulin resistance in children with idiopathic growth 
hormone deficiency during 12 months of growth hormone treat-
ment. J Endocrinol Invest Oct 2 (Epub ahead of print)
 27. Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo 
D, Spinelli L, Muzzica S, Lombardi G, Colao A (2006) Improve-
ment of cardiac performance and cardiovascular risk factors in 
children with GH deficiency after two years of GH replacement 
therapy: an observational, open, prospective, case-control study. 
J Clin Endocrinol Metab 91(4):1288–1295
 28. Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, 
Loche S, Severi F (1999) Growth hormone (GH) deficiency 
(GHD) of childhood onset: reassessment of GH status and evalu-
ation of the predictive criteria for permanent GHD in young 
adults. J Clin Endocrinol Metab 84(4):1324–1328
 29. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Bal-
samo A, Gualandi S, Cicognani A (2006) Effect on adult height 
of pubertal growth hormone retesting and withdrawal of therapy 
in patients with previously diagnosed growth hormone defi-
ciency. J Clin Endocrinol Metab 91(11):4271–4276
 30. Secco A, di Iorgi N, Napoli F, Calandra E, Calcagno A, Ghezzi 
M, Frassinetti C, Fratangeli N, Parodi S, Benassai M, Leitner Y, 
Gastaldi R, Lorini R, Maghnie M, Radetti G (2009) Reassess-
ment of the growth hormone status in young adults with child-
hood-onset growth hormone deficiency: reappraisal of insulin 
tolerance testing. J Clin Endocrinol Metab 94(11):4195–4204
 31. Arafat AM, Möhlig M, Weickert MO, Schöfl C, Spranger J, 
Pfeiffer AF (2010) Improved insulin sensitivity, preserved beta 
cell function and improved whole-body glucose metabolism 
after low-dose growth hormone replacement therapy in adults 
with severe growth hormone deficiency: a pilot study. Diabetolo-
gia 53(7):1304–1313
Author's personal copy
